Floatz logo

Palifermin

Radiation Toxicity

Jonsson Comprehensive Cancer Centerprotein_peptidePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Radiation Toxicity cohort.

Asset / SponsorPhaseRating
FILGRASTIM
IRCCS San Raffaele
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-sen University
Phase 3BB
Amifostine
Alliance for Clinical Trials in Oncology
Phase 3BB
ETOPOSIDE
Sun Yat-sen University
Phase 3BB
Carboplatin
Sun Yat-sen University
Phase 3BB

View all 37 →

Same molecule, other indications

Palifermin is also rated in:

mucositisDormant
BB
Indicative ·
64 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
63 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →